ArticleMikrochimica acta2025
A label-free electrochemical immunosensor on gold-printed electrode for the electrochemical detection of C-reactive protein from blood samples.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Chitosan-Modified Gold Nanoparticle-Based Electrochemical Immunosensor for C-Reactive Protein Detection.Bioengineering (Basel, Switzerland) · 2026Article
- MWCNT-Au-Pt hybrid nanocomposite-based electrochemical immunosensor for FGF-2 detection: a novel strategy for anxiety disorder diagnosis.Analytical and bioanalytical chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fabrication of a simple, label-free, electrochemical immunosensor for C-reactive protein (CRP) detection is presented using a custom-designed printed circuit board (PCB) gold electrode. To enhance the sensitivity of the sensing platform, the surface of the gold working electrode was modified with multi-walled carbon nanotubes (MWCNTs), leveraging its exceptional conductivity and biocompatibility. The label-free immunosensor operates on immunological principles, with anti-CRP antibodies covalently immobilized on the modified electrode to capture and quantify CRP levels, using differential pulse voltammetry (DPV). The immunosensor demonstrated high specificity to CRP, exhibiting a linear detection range of 1.25 to 80 μg/mL of CRP in 1 × PBS, and achieving a detection limit (LOD) of 0.745 µg/mL within 30 min. Notably, the immunosensor successfully detected CRP in human ethylenediaminetetraacetic acid (EDTA)-anticoagulated whole blood with a detection limit of 0.177 µg/mL, which is within the clinical range for sepsis (5 µg/mL). Furthermore, this immunosensor was able to detect CRP using only 2 µL of EDTA-anticoagulated whole blood samples. These findings highlight the potential of the CRP immunosensor platform for point-of-care (POC) testing in clinical settings, owing to its simple fabrication, ease of operation, low cost, and robust performance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.